Thomopoulos Thomas P, Symeonidis Argiris, Kourakli Alexandra, Papageorgiou Sotirios G, Pappa Vasiliki
Second Department of Internal Medicine, Attikon Hospital, Research Institute, National and Kapodistrian University of Athens, Athens, Greece.
Department of Internal Medicine, University Hospital of Patras, Rio, Greece.
Front Oncol. 2022 Apr 14;12:891961. doi: 10.3389/fonc.2022.891961. eCollection 2022.
Chronic neutrophilic leukemia (CNL) represents a rare disease, that has been classified among the BCR/ABL-negative myeloproliferative neoplasms. The disease is characterized by marked leukocytosis with absolute neutrophilia and its clinical presentation may vary from asymptomatic to highly symptomatic with massive splenomegaly and constitutional symptoms. CNL prognosis remains relatively poor, as most patients succumb to disease complications or transform to acute myeloid leukemia. Recent studies have demonstrated that mutations drive the disease, albeit the presence of other secondary mutations perplex the genetic landscape of the disease. Notably, the presence of mutations has been adopted as a criterion for diagnosis of CNL. Despite the vigorous research, the management of the disease remains suboptimal. Allogeneic stem cell transplantation represents the only treatment that could lead to cure; however, it is accompanied by high rates of treatment-related mortality. Recently, ruxolitinib has shown significant responses in patients with CNL; however, emergence of resistance might perturbate long-term management of the disease. The aim of this review is to summarize the clinical course and laboratory findings of CNL, highlight its pathogenesis and complex genetic landscape, and provide the context for the appropriate management of patients with CNL.
慢性中性粒细胞白血病(CNL)是一种罕见疾病,已被归类于BCR/ABL阴性骨髓增殖性肿瘤。该疾病的特征是明显的白细胞增多伴绝对中性粒细胞增多,其临床表现从无症状到出现高度症状,伴有巨大脾肿大和全身症状不等。CNL的预后仍然相对较差,因为大多数患者死于疾病并发症或转化为急性髓系白血病。最近的研究表明,某些突变驱动了该疾病,尽管其他继发性突变的存在使该疾病的遗传格局变得复杂。值得注意的是,某些突变的存在已被用作CNL诊断的标准。尽管进行了大量研究,但该疾病的管理仍然不尽人意。异基因干细胞移植是唯一可能治愈的治疗方法;然而,它伴随着较高的治疗相关死亡率。最近,鲁索替尼在CNL患者中显示出显著疗效;然而,耐药性的出现可能会干扰该疾病的长期管理。本综述的目的是总结CNL的临床病程和实验室检查结果,突出其发病机制和复杂的遗传格局,并为CNL患者的适当管理提供背景信息。